Health
Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine
Teva Canada Limited (Teva Canada) announced today that Health Canada has approved an expanded indication for PrAJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 years and weighing at least 45 kg. With this approval, PrAJOVY® becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for eligible pediatric patients, marking a meaningful advancement
![Teva Canada Announces Approval of Expanded Indication of [Pr]AJOVY® (fremanezumab solution for subcutaneous injection), the First Anti-CGRP Preventive Treatment for Pediatric Episodic Migraine](https://media.zenfs.com/en/cnwgroup.com/3e3ad5b9e454d81761620224c02b0901)
About this update from Teva Pharmaceutical Industries Limited
[{"type":"list","items":[{"val":[{"type":"text","content":"Health Canada approves PrAJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 years and weighing at least 45 kg.","length":242,"tagName":"p"}]},{"val":[{"type":"text","content":"PrAJOVY® increases availability across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine prevention and migraine prevention in adults.","length":208,"tagName":"p"}]},{"val":[{"type":"text","content":"This approval marks an important step in enhancing the impact of PrAJOVY® beyond adults since its Canadian approval in 2020, and underscores Teva's ongoing efforts to advance and address neurological challenges.","length":215,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":665,"olType":false},{"type":"text","content":"TORONTO, Feb. 4, 2026 /CNW/ - Teva Canada Limited (Teva Canada) announced today that Health Canada has approved an expanded indication for PrAJOVY® (fremanezumab solution for subcutaneous injection) for the prevention of episodic migraine (fewer than 15 migraine days per month) in pediatric patients aged 6 to 17 years and weighing at least 45 kg. With this approval, PrAJOVY® becomes the first and only calcitonin gene-related peptide (CGRP) antagonist indicated for eligible pediatric patients, marking a meaningful advancement in expanding preventive treatment options for those living with migraine.","length":614,"tagName":"p"},{"type":"image","alt":"[Pr]AJOVY® (CNW Group/Teva Canada)","displaySize":"","headline":null,"caption":"[Pr]AJOVY® (CNW Group/Teva Canada)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":266,"url":"https://media.zenfs.com/en/cnwgroup.com/3e3ad5b9e454d81761620224c02b0901"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/scP5ClJJz47pHSUOExwPlA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2OTtjZj13ZWJw/https://media.zenfs.com/en/cnwgroup.com/3e3ad5b9e454d81761620224c02b0901","width":400,"height":266}},"href":"https://mma.prnewswire.com/media/2876258/Teva_Canada_Teva_Canada_Announces_Approval_of_Expanded_Indicatio.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Migraine is a neurological disease that significa...